MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2

BACKGROUND: Chemotherapy based on paclitaxel (PTX) is the standard treatment for a range of cancers, including triple-negative breast cancer (TNBC), but the increasing development of resistance has reduced/has negatively impacted its clinical utility. A previous study demonstrated that miR-5195-3p c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mei, Gong, Can, Xu, Renyuan, Chen, Yu, Wang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604428/
https://www.ncbi.nlm.nih.gov/pubmed/31308851
http://dx.doi.org/10.1186/s11658-019-0168-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604428/
https://www.ncbi.nlm.nih.gov/pubmed/31308851
http://dx.doi.org/10.1186/s11658-019-0168-7

Ejemplares similares